Posizioni attive di Timothy Perera
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
DeuterOncology SA
 DeuterOncology SA BiotechnologyHealth Technology DeuterOncology SA is a Belgian preclinical-stage biotechnology company that specializes in developing targeted cancer therapies. DeuterOncology is based in Liege, BE. The company's focus is on creating a first-in-class dual MET and RAS pathway inhibitor. The company was founded in 2020 by Timothy Perera, who has been the CEO since 2020. | Direttore/Membro del Consiglio | 01/09/2020 | - |
| Amministratore Delegato | 01/09/2020 | - | |
| Fondatore | 01/09/2020 | - |
Storia della carriera di Timothy Perera
Precedenti posizioni note di Timothy Perera
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
OCTIMET Oncology NV
 OCTIMET Oncology NV BiotechnologyHealth Technology OCTIMET Oncology NV develops MET kinase inhibitors for the treatment of cancer. The company was founded by Timothy Perera, Ann Louise Meulemans, Paolo Comoglio, and Philip Owen in 2016 and is headquartered in Beerse, the Netherlands. | Amministratore Delegato | 01/01/2016 | - |
| Fondatore | 01/01/2016 | - |
Statistiche
Distribuzione geografica
| Belgio | 3 |
Posizioni
| Chief Executive Officer | 2 |
| Founder | 2 |
| Director/Board Member | 1 |
Settori
| Health Technology | 3 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Aziende private | 2 |
|---|---|
OCTIMET Oncology NV
OCTIMET Oncology NV BiotechnologyHealth Technology OCTIMET Oncology NV develops MET kinase inhibitors for the treatment of cancer. The company was founded by Timothy Perera, Ann Louise Meulemans, Paolo Comoglio, and Philip Owen in 2016 and is headquartered in Beerse, the Netherlands. | Health Technology |
DeuterOncology SA
DeuterOncology SA BiotechnologyHealth Technology DeuterOncology SA is a Belgian preclinical-stage biotechnology company that specializes in developing targeted cancer therapies. DeuterOncology is based in Liege, BE. The company's focus is on creating a first-in-class dual MET and RAS pathway inhibitor. The company was founded in 2020 by Timothy Perera, who has been the CEO since 2020. | Health Technology |
- Borsa valori
- Insiders
- Timothy Perera
- Esperienza
